Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
26.86
-0.14 (-0.54%)
Streaming Delayed Price
Updated: 1:10 PM EDT, Jun 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
December 18, 2023
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...
Via
Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is One of Monday Morning’s Most Active Stocks
December 18, 2023
Via
Investor Brand Network
Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
↗
December 18, 2023
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in...
Via
Benzinga
What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics
↗
November 06, 2023
Via
Benzinga
Earnings Outlook For Arcutis Biotherapeutics
↗
November 02, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
December 18, 2023
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Via
InvestorPlace
FDA Approves Arcutis Biotherapeutics' Lead Drug For Scaly Skin Disorder
↗
December 18, 2023
The FDA approved Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) Zoryve (roflumilast) topical foam, 0.3% for seborrheic dermatitis in individuals
Via
Benzinga
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 15, 2023
Via
Benzinga
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks With Key Catalysts Coming in December
↗
November 15, 2023
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.
Via
InvestorPlace
DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For Monday
↗
November 06, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 03, 2023
Via
Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In November
↗
November 03, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
MSP Recovery And 3 Other Stocks Under $3 Insiders Are Buying
↗
October 27, 2023
The Dow Jones closed lower by over 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Earnings Scheduled For November 3, 2023
↗
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Nasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook
↗
October 20, 2023
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Friday. The Dow traded down 0.61% to 33,209.97 while the NASDAQ fell 1.24% to 13,022.16. The S&P...
Via
Benzinga
Topics
Stocks
Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
October 20, 2023
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday.
Via
Benzinga
Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results
↗
October 20, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.31% to 33,309.28 while the NASDAQ fell 1.09% to 13,042.83. The S&P 500 also...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 20, 2023
Via
Benzinga
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
↗
October 20, 2023
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
October 20, 2023
We're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching on Friday morning!
Via
InvestorPlace
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 19, 2023
Via
Benzinga
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
↗
October 13, 2023
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
